Skip Navigation

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow E-letters: Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when E-letters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Search for citing articles in:
ISI Web of Science (17)
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by Limat, S.
Right arrow Articles by Cahn, J. Y.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Limat, S.
Right arrow Articles by Cahn, J. Y.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

Annals of Oncology 14:277-281, 2003
© 2003 European Society for Medical Oncology

Original Paper

Early cardiotoxicity of the CHOP regimen in aggressive non-Hodgkin’s lymphoma

S. Limat1, K. Demesmay1, L. Voillat2, Y. Bernard3, E. Deconinck2, A. Brion2, A. Sabbah4, M. C. Woronoff-Lemsi1 and J. Y. Cahn2,+

Departments of 1 Pharmacy, 2 Hematology, 3 Cardiology and 4 Nuclear Medicine, Besançon University Hospital, Besançon, France

Received 23 April 2002; revised 12 August 2002; accepted 16 September 2002

Background:

To determine the incidence of early cardiotoxicity induced by the CHOP regimen in patients with aggressive non-Hodgkin’s lymphoma (NHL) and to identify associated risk factors.

Patients and methods:

A retrospective analysis included 135 consecutive patients who had been treated with the CHOP (cyclophosphamide, doxorubicin, vincristin, prednisone) regimen as first-line therapy between 1994 and 2000. The cardiac evaluation was based on a determination of the resting left ventricular ejection function (LVEF) by gated blood-pool imaging. Cardiotoxicity was defined as a significant decrease in LVEF or clinical evidence of congestive heart failure (CHF).

Results:

Twenty-seven (20%) patients developed a cardiac event within 1 year of treatment. Among these, 14 patients had clinical signs of CHF. Three patients died suddenly from presumed cardiac causes. In multivariate analysis, a cumulative dose of doxorubicin >200 mg/m2 [odds ratio (OR) = 4.2, P = 0.005)] and age over 50 years (OR = 2.9, P = 0.03) appeared to be significant risk factors.

Conclusion:

Early clinical and subclinical cardiotoxicity was frequent in patients receiving the CHOP regimen. The threshold of the cumulative dose of doxorubicin appeared to be low: at doses >200 mg/m2, 27% of patients had cardiac events. Elderly patients appeared to be at higher risk. The development of cardioprotective strategies or alternative treatments are mandatory for aggressive NHL patients.

Key words: cardioprotection, cardiotoxicity, congestive heart failure, doxorubicin, non-Hodgkin’s lymphoma


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
 JCOHome page
D. L. Hershman, R. B. McBride, A. Eisenberger, W. Y. Tsai, V. R. Grann, and J. S. Jacobson
Doxorubicin, Cardiac Risk Factors, and Cardiac Toxicity in Elderly Patients With Diffuse B-Cell Non-Hodgkin's Lymphoma
J. Clin. Oncol., July 1, 2008; 26(19): 3159 - 3165.
[Abstract] [Full Text] [PDF]

Home page
 Journal of Pharmacy PracticeHome page
B. L. Frei and S. A. Soefje
A Review of the Cardiovascular Effects of Oncology Agents
Journal of Pharmacy Practice, April 1, 2008; 21(2): 146 - 158.
[Abstract] [PDF]

Home page
 JCOHome page
O. Hequet, Q.H. Le, I. Moullet, E. Pauli, G. Salles, D. Espinouse, C. Dumontet, C. Thieblemont, P. Arnaud, D. Antal, et al.
Subclinical Late Cardiomyopathy After Doxorubicin Therapy for Lymphoma in Adults
J. Clin. Oncol., May 15, 2004; 22(10): 1864 - 1871.
[Abstract] [Full Text] [PDF]


Disclaimer:
Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.